drug co shenanigans: dm meds
A recent analysis found huge corporate profits by drug companies that make an array of diabetes meds, far exceeding the actual real costs of their manufacture (see dm meds drug co shenanigans in dropbox, or doi:10.1001/jamanetworkopen.2024.3474) Details : -- these researchers evaluated the “sustainable cost-based prices (CBPs) of insulins, SGLT-2s (sodium-glucose cotransporter-2 inhibitors) and GLP1’s (glucagonlike peptide-1 agonists), and compared them to their current lowest reported prices in 13 countries. -- their methodology of determining the sustainable CBPs: -- the actual pharmaceutical ingredient (API) cost per unit -- the costs of formulation and other operating expenses (including packaging and logistical costs) -- a profit margin with allowance for taxes -- and the ultimate prices charged should reflect “competitive markets that afford manufacturers sustainabl...